Cookies disclaimer

I agree Our site saves small pieces of text information (cookies) on your device in order to deliver better content and for statistical purposes. You can disable the usage of cookies by changing the settings of your browser. By browsing our website without changing the browser settings you grant us permission to store that information on your device.


Mabion S.A. has started recruitment to new randomized, double-blind clinical study MabionCD20-003RA (MABRIDGE) comparing primarily pharmacokinetics and safety of MabionCD20 (biosimilar to rituximab) with the EU- and US-licensed reference drug (MabThera and Rituxan) in patients with moderate to serve Rheumatoid Arthritis. The recruitment has already started in Belgium, Czech Republic, Lithuania, Ukraine, Poland and Georgia.

This clinical study aims to support the approval of MabionCD20 on the US market as a biosimilar drug product to Rituxan and on the EU market as a biosimilar drug to MabThera.



© Mabion S.A. all rights reserved Polityka Prywatności